E Fund Management Co., Ltd. Bluebird Bio, Inc. Transaction History

E Fund Management Co., Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	BUY	$1.32 - $4.83 $4,060 - $14,857	3,076 Added 4.59%	70,054 $96,000
Q3 2023 Nov 13, 2023	SELL	$3.02 - $4.05 $65,268 - $87,528	-21,612 Reduced 24.4%	66,978 $204,000
Q2 2023 Aug 11, 2023	SELL	$2.79 - $5.03 $9,912 - $17,871	-3,553 Reduced 3.86%	88,590 $291,000
Q1 2023 May 11, 2023	BUY	$3.14 - $8.22 $112,132 - $293,544	35,711 Added 63.28%	92,143 $293,000
Q4 2022 Feb 14, 2023	SELL	$5.77 - $8.49 $59,332 - $87,302	-10,283 Reduced 15.41%	56,432 $391,000
Q3 2022 Nov 14, 2022	BUY	$3.75 - $7.39 $250,181 - $493,023	66,715 New	66,715 $422,000
Q2 2022 Aug 15, 2022	SELL	$2.94 - $5.23 $144,409 - $256,892	-49,119 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$4.07 - $10.6 $121,143 - $315,509	29,765 Added 153.79%	49,119 $238,000
Q4 2021 Feb 11, 2022	BUY	$8.96 - $16.31 $135,098 - $245,922	15,078 Added 352.62%	19,354 $193,000
Q1 2021 May 12, 2021	BUY	$16.59 - $33.89 $70,938 - $144,913	4,276 New	4,276 $83,000

146

63.3M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $644M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.